Incorrect password
evipedia.ai Suggest Edit

Cathelicidin LL-37 for Health & Longevity

Evidence Review created on 04/20/2026 using AI4L / Opus 4.7

Also known as: LL-37, hCAP-18, CAP-18, Human Cathelicidin, CAMP peptide

Motivation

Cathelicidin LL-37 is the only cathelicidin antimicrobial peptide found in humans. It is a short, positively charged peptide made by neutrophils, skin cells, and other immune and barrier tissues, acting as a first-line defender against bacteria, viruses, and fungi while also shaping inflammation and tissue repair.

Interest in LL-37 beyond basic immunology has grown for two reasons. Its production depends strongly on vitamin D, linking it to a nutrient that influences infection resistance and skin health. Synthetic LL-37 has also entered the unregulated peptide market, promoted via injection or topical cream for immune support and wound healing, despite a narrow clinical evidence base.

This review examines what is known about LL-37 as both an endogenous peptide that can be modulated through vitamin D status and as an exogenously administered peptide therapy. It looks at the biology, the human trial evidence, safety signals from conditions where LL-37 is overexpressed, and the practical considerations that matter when evaluating LL-37 in a longevity context.

Benefits - Risks - Protocol - Conclusion

This section lists high-level, directly relevant overviews of LL-37 from experts, podcasters, and narrative reviewers.

No dedicated in-depth content on LL-37 was found on foundmyfitness.com (Rhonda Patrick), hubermanlab.com standalone (Andrew Huberman personal coverage), chriskresser.com (Chris Kresser), or lifeextension.com (Life Extension Magazine) as of this review; LL-37 is discussed only tangentially within broader vitamin D or peptide content on these platforms.

Grokipedia

  • Cathelicidin antimicrobial peptide

    Comprehensive encyclopedic entry covering the cathelicidin family, the CAMP gene, processing of hCAP-18 into LL-37, structural conformations, antimicrobial mechanisms, immune modulation, vitamin D regulation, and disease associations.

Examine

No article for Cathelicidin LL-37 exists on Examine.com.

ConsumerLab

No article for Cathelicidin LL-37 exists on ConsumerLab.com.

Systematic Reviews

The following systematic reviews and meta-analyses examine LL-37 biology, expression, and clinical associations.

Mechanism of Action

LL-37 is a 37-amino-acid amphipathic α-helical peptide cleaved from its precursor hCAP-18 (human cationic antimicrobial protein, 18 kDa), the only cathelicidin encoded in the human genome (CAMP gene (cathelicidin antimicrobial peptide gene, the sole gene producing human cathelicidin) on chromosome 3). Its net positive charge allows it to bind negatively charged bacterial membranes, cause pore formation, and disrupt microbial viability across Gram-positive bacteria, Gram-negative bacteria, enveloped viruses, and fungi.

The primary mechanisms include:

  • Direct membrane disruption: Electrostatic attraction to microbial membranes followed by oligomerization and pore or carpet-like lysis, producing broad-spectrum antimicrobial activity including against antibiotic-resistant strains.

  • Immune modulation: LL-37 acts on the formyl peptide receptor FPR2 (also called FPRL1, a G-protein-coupled receptor that guides immune-cell chemotaxis) and related receptors to recruit neutrophils, monocytes, and T cells; it can both suppress TLR2/TLR4 (toll-like receptors 2 and 4, innate immune sensors for bacterial components)-driven LPS (lipopolysaccharide, a component of Gram-negative bacterial outer membranes) inflammation and, at higher concentrations, amplify certain inflammatory signals.

  • Neutrophil extracellular trap (NET) regulation: LL-37 promotes the formation and clearance of NETs, web-like structures neutrophils release to trap pathogens. Dysregulated NETs contribute to thrombosis and autoimmunity; balanced LL-37 activity appears protective.

  • Wound healing and angiogenesis: LL-37 drives keratinocyte migration and proliferation, stimulates vascular endothelial growth factor signaling, and supports granulation tissue formation.

  • LPS neutralization: Direct binding and sequestration of LPS, reducing sepsis-associated cytokine storm in preclinical models.

Two competing mechanistic narratives exist in the literature and both have support. The “LL-37 as a protective antimicrobial and pro-healing agent” view is backed by infection, wound-healing, and sepsis studies. The “LL-37 as a driver of sterile inflammation” view is backed by psoriasis, rosacea, atherosclerosis, and lupus data, where overexpressed or aberrantly processed LL-37 binds self-nucleic acids (DNA, RNA) and triggers type-I interferon responses, inflammasome activation, and autoantibody formation. LL-37’s effect is dose-, context-, and tissue-dependent rather than uniformly beneficial.

LL-37 is a short peptide with a plasma half-life measured in minutes to a few hours after systemic administration, due to rapid proteolytic degradation. It is not orally bioavailable in intact form. There are no human CYP-mediated metabolism data because clearance is via peptidase digestion rather than hepatic enzymes. Endogenous LL-37 expression is induced primarily by the active form of vitamin D (1,25-dihydroxyvitamin D3) acting through a vitamin D response element in the CAMP gene promoter, by short-chain fatty acids such as butyrate, by the histone deacetylase inhibitor phenylbutyrate, and by certain microbial products. Vitamin D deficiency is a well-documented cause of blunted LL-37 production.

Historical Context & Evolution

LL-37 was identified in the mid-1990s as the human homolog of cathelicidin peptides already characterized in other mammals. The first descriptions focused on its role as a natural antibiotic: a small, inducible, broad-spectrum effector of innate immunity expressed by neutrophils and epithelia at sites of infection or injury.

The second wave of research established the vitamin D connection. Studies in the early 2000s showed that toll-like receptor activation of macrophages upregulates the vitamin D receptor and the enzyme CYP27B1 (which converts 25-hydroxyvitamin D to the active 1,25-dihydroxyvitamin D), leading to cathelicidin induction and killing of intracellular Mycobacterium tuberculosis. This gave a plausible mechanism linking vitamin D status to infection resistance and shifted LL-37 from pure immunology into nutrition and public health.

A third research wave revealed the dark side of LL-37. Work on psoriasis showed that LL-37 complexed with self-DNA triggers plasmacytoid dendritic cell interferon production; lupus and rheumatoid arthritis research identified LL-37 as an autoantigen; rosacea research tied aberrant kallikrein-mediated LL-37 processing to chronic facial inflammation. Rather than being a uniformly protective peptide, LL-37 emerged as a context-dependent signal: protective when regulated, pathogenic when overexpressed or abnormally processed.

Most recently, LL-37 has entered the gray-market peptide therapy space. Clinicians providing peptide protocols have promoted synthetic LL-37 for chronic Lyme disease, mold-related illness, biofilm-resistant infections, gut inflammation, and general immune support. This clinical usage has far outpaced the published human evidence, which remains dominated by topical and in-vitro studies. The current scientific picture is that LL-37 is biologically important, therapeutically plausible in narrow indications, and not yet validated as a broad longevity intervention.

Expected Benefits

High 🟩 🟩 🟩

Enhanced Topical Wound Healing (Diabetic Foot Ulcers)

Topical LL-37 cream enhances healing of mild-infection diabetic foot ulcers, evaluated in a randomized double-blind placebo-controlled trial. LL-37 promotes keratinocyte migration and proliferation, drives angiogenesis, and provides local antimicrobial activity. The primary human evidence is the NCT04098562 trial showing greater granulation index at weeks 1, 2, 3, and 4 with twice-weekly LL-37 cream versus placebo. Benefit was site-specific and required pre-existing low endogenous LL-37; it does not generalize to systemic wound healing.

Magnitude: In the trial, the granulation index was significantly higher in the LL-37 group on day 7 (p = 0.031), day 14 (p = 0.009), day 21 (p = 0.006), and day 28 (p = 0.037) compared to placebo.

Medium 🟩 🟩

Broad-Spectrum Antimicrobial Activity

LL-37 kills Gram-positive bacteria, Gram-negative bacteria, fungi, and enveloped viruses in vitro, including multi-drug-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Candida species. The mechanism is direct membrane disruption via cationic binding and pore formation, making classical resistance mutations less likely. Most evidence is in vitro and in animals; human data are largely confined to correlation studies of endogenous LL-37 levels with infection outcomes.

Magnitude: In vitro MIC (minimum inhibitory concentration, the lowest drug concentration preventing visible microbial growth) values for LL-37 range approximately 1–50 µg/mL against susceptible organisms, though activity drops substantially in physiological salt and serum conditions.

Immunomodulation in Respiratory and Systemic Infection

Circulating LL-37 levels correlate with infection resistance in tuberculosis, respiratory infections, and sepsis. The mechanism involves LPS neutralization, NET regulation, and suppression of excessive TLR-driven cytokine release. Evidence is strongest from the Acen et al. meta-analysis linking vitamin-D-dependent LL-37 expression to TB outcomes, plus systematic reviews in sepsis. The data support LL-37 as an innate-immunity marker and target, but exogenous LL-37 has not been shown in human trials to reduce infection rates.

Magnitude: Not quantified in available studies.

Low 🟩

Biofilm Disruption

LL-37 disrupts bacterial and fungal biofilms at sub-inhibitory concentrations by interfering with quorum-sensing and attachment, relevant for chronic wound, dental, and device-associated infection. Evidence is from in-vitro and animal models; no adequately powered human trials confirm a clinical anti-biofilm effect for exogenous LL-37.

Magnitude: Biofilm mass reductions of 40–80% are reported in vitro at concentrations of 1–10 µg/mL against P. aeruginosa and S. aureus biofilms, with substantial variation by strain and biofilm maturity.

Cutaneous Immune Resilience in Atopic Dermatitis

Low cathelicidin expression in atopic dermatitis skin allows Staphylococcus aureus colonization; raising LL-37 (via topical or vitamin D) reduces S. aureus density and may improve barrier function. The mechanism is restoration of a deficient antimicrobial shield. Evidence is mixed: small oral vitamin D trials show biomarker movement, but clinical improvement is inconsistent and no direct exogenous LL-37 trial has been completed for atopic dermatitis.

Magnitude: Small studies report S. aureus colonization reductions of roughly 40–60% with cathelicidin-boosting interventions, without consistent clinical severity improvement.

Anti-Tumor Activity in Specific Cancers

LL-37 induces selective cytotoxicity in some cancer cell lines (breast, colon, melanoma) via membrane disruption and apoptosis pathways, and intratumoral LL-37 has been tested in a phase I/II melanoma trial (NCT02225366). Mechanisms include enhanced antigen presentation and innate immune recruitment. The melanoma trial completed with only 3 participants starting treatment and 2 completing (registered enrollment target of 4), limiting inferences; preclinical data are more extensive but LL-37 has a dual pro-/anti-tumor profile.

Magnitude: Not quantified in available studies.

Speculative 🟨

Gut-Barrier Repair and Intestinal Immunity

Clinical protocols promote LL-37 for leaky gut, IBD (inflammatory bowel disease, a chronic gut inflammatory disorder), and SIBO (small intestinal bacterial overgrowth). The theoretical basis includes LL-37’s role in epithelial defense and sodium butyrate’s ability to induce endogenous LL-37 in colon mucosa (NCT00800930). No randomized trial has tested exogenous LL-37 for gut conditions; evidence is mechanistic and anecdotal.

Chronic Lyme, Mold, and Biotoxin Illness Support

Integrative and functional medicine practices offer LL-37 for chronic Lyme disease, chronic inflammatory response syndrome (a proposed multi-system condition attributed by some clinicians to biotoxin exposure such as mold), and mold-related illness. The rationale is its anti-biofilm activity against persistent Borrelia forms and its broad antimicrobial spectrum. No controlled clinical trials support these uses in humans.

General Longevity and Immunosenescence

LL-37 declines with age in some tissues, and its role in clearing cellular debris, resolving inflammation, and supporting barrier integrity has prompted speculation about relevance to healthspan. No longitudinal human studies link exogenous LL-37 to markers of biological aging, and the pro-inflammatory risk profile (discussed below) is a significant countervailing consideration.

Benefit-Modifying Factors

  • Vitamin D status: Endogenous LL-37 expression is strongly vitamin-D-dependent. 25-hydroxyvitamin D levels below approximately 30 ng/mL blunt cathelicidin induction; correcting deficiency restores baseline LL-37 production and may be a prerequisite for any LL-37-dependent benefit, whether endogenous or synergistic with exogenous dosing.

  • Baseline LL-37 levels: In the diabetic foot ulcer trial, baseline wound LL-37 levels were low in both groups before topical application produced benefit; individuals with already-elevated LL-37 (e.g., in chronic psoriatic or rosaceic skin) are unlikely to benefit and may be harmed by additional LL-37.

  • Sex-based differences: LL-37 is produced by both sexes, but some studies report modestly higher cathelicidin expression in males and estrogen-related modulation in females; no sex-stratified efficacy data are available for exogenous LL-37.

  • Pre-existing inflammatory or autoimmune conditions: Individuals with psoriasis, rosacea, cutaneous lupus, rheumatoid arthritis, or atherosclerosis likely have elevated or aberrantly processed LL-37 at baseline; exogenous LL-37 is expected to worsen rather than improve outcomes in these populations.

  • Age-related considerations: Aging is associated with increased basal inflammation, sometimes termed inflammaging, with altered neutrophil function and NET dysregulation. Older adults at the upper end of the target range may have reduced benefit and increased susceptibility to pro-inflammatory LL-37 effects, particularly on vascular and skin tissue.

  • Vitamin D receptor polymorphisms: VDR (vitamin D receptor) variants such as FokI, BsmI, TaqI, and ApaI (common single-nucleotide variants in the VDR gene that alter receptor function or expression) alter vitamin-D-mediated cathelicidin induction and may modify responsiveness to vitamin D as an upstream LL-37 lever.

  • Smoking and alcohol status: Smoking and chronic alcohol exposure dysregulate LL-37 in saliva, gingival fluid, and blood (per Rojas-Pirela 2026), shifting baseline levels and potentially the therapeutic window.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Triggering or Worsening of Rosacea-Like Inflammation

LL-37 drives the NLRP3 (a multi-protein inflammasome complex) inflammasome and mast-cell degranulation via TLR2/JAK2/STAT3 (Janus kinase 2 / signal transducer and activator of transcription 3, a cytokine-driven intracellular signaling pathway) signaling, producing papulopustular inflammation, facial erythema, and telangiectasia (visible small blood vessels). Mechanistically, elevated or aberrantly processed LL-37 is a central pathogenic factor in rosacea. Evidence includes preclinical mouse models of LL-37-induced rosacea-like inflammation and systematic biomarker reviews consistently identifying LL-37 elevation in rosacea patients.

Magnitude: Not quantified in available studies.

Exacerbation of Psoriasis and Psoriatic Arthritis

LL-37 is a major T-cell autoantigen in moderate-to-severe plaque psoriasis; roughly two-thirds of patients carry CD4+ or CD8+ T cells specific for LL-37. LL-37 also complexes with self-DNA to activate plasmacytoid dendritic cells and drive type-I interferon production that sustains psoriatic plaques. Evidence includes multiple mechanistic studies and autoantibody cohort data. Exogenous LL-37 in a predisposed individual is plausibly harmful.

Magnitude: Not quantified in available studies.

Medium 🟥 🟥

Autoimmune Disease Flare (Lupus, Rheumatoid Arthritis)

LL-37 is an autoantigen in systemic lupus erythematosus, with anti-LL-37 antibodies identified in subsets of patients, and it contributes to rheumatoid arthritis via NET-driven autoimmunity. The mechanism involves LL-37-DNA complex recognition by plasmacytoid dendritic cells and interferon signaling. Evidence from case-control biomarker studies and mechanistic work supports caution; no trial has tested exogenous LL-37 in autoimmune populations.

Magnitude: Not quantified in available studies.

Pro-Thrombotic Signaling ⚠️ Conflicted

LL-37 can potentiate coagulation factor activity and contribute to microthrombosis, as shown in COVID-19 patient plasma studies. Mechanistically, LL-37 enhances platelet activation and binds to coagulation components. Evidence is conflicted: some groups propose LL-37 upregulation as therapeutic in COVID-19 because it promotes NET clearance and endothelial repair, while others report LL-37 elevation as a thrombotic driver. Human data are observational; no randomized exogenous LL-37 trial has measured thrombotic endpoints.

Magnitude: Not quantified in available studies.

Injection Site Reactions

Subcutaneous administration of gray-market LL-37 produces local redness, induration, itching, and welts, likely through mast cell activation at the injection site. Evidence is from clinic and patient-reported data within peptide-therapy practices; no pharmacovigilance system tracks gray-market peptide adverse events systematically.

Magnitude: Not quantified in available studies.

Low 🟥

Unknown Long-Term Oncogenic and Tumor-Modulating Effects

LL-37 has pro-tumorigenic effects in some cancers (ovarian, lung, breast, colon) via ERK (extracellular signal-regulated kinase, a growth-related signaling enzyme), FPR2, and EGFR (epidermal growth factor receptor) signaling, and anti-tumor effects in others. The balance depends on cancer type, microenvironment, and LL-37 concentration. Evidence is largely preclinical; long-term human safety data for exogenous LL-37 do not exist.

Magnitude: Not quantified in available studies.

Atherosclerosis Progression

LL-37 is present in atherosclerotic plaques and colocalizes with macrophages; it may recruit additional inflammatory cells and destabilize plaques. Evidence is observational and mechanistic. Whether exogenous LL-37 accelerates atherosclerosis in humans is not established.

Magnitude: Not quantified in available studies.

Speculative 🟨

Contamination, Endotoxin Exposure, and Sterility Risk

Gray-market peptide vials are not regulated for sterility, endotoxin load, or identity. Subcutaneous injection of contaminated material can cause local infection, systemic pyrogenic reactions, and in rare cases sepsis. Evidence is primarily from regulator statements and case reports in the broader gray-market peptide space; LL-37-specific contamination incidents are not systematically tracked.

Development of Anti-LL-37 Autoantibodies

Repeated exogenous exposure to LL-37 in immunologically predisposed individuals could theoretically induce anti-LL-37 antibodies similar to those seen in lupus and psoriatic arthritis, potentially unmasking or precipitating autoimmunity. No human data directly test this.

Risk-Modifying Factors

  • Pre-existing inflammatory skin disease: Psoriasis, rosacea, seborrheic dermatitis, and hidradenitis suppurativa (a chronic inflammatory skin condition causing painful nodules and abscesses in skin-fold areas) indicate elevated endogenous LL-37 and substantially elevated risk of flare with exogenous administration.

  • Baseline autoimmune status: History of lupus, rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, or positive ANA (antinuclear antibody, a blood marker of autoimmunity) increases risk of autoimmune flare.

  • Sex-based differences: Women have a several-fold higher baseline risk of autoimmune disease (lupus, rheumatoid arthritis) and may be at disproportionately higher autoimmune-flare risk on exogenous LL-37.

  • Atherosclerotic cardiovascular disease: Established coronary or carotid atherosclerosis is a theoretical contraindication because LL-37 accumulates in plaques and may promote local inflammation.

  • Age-related considerations: Older adults (65+) have higher rates of autoimmune seropositivity, atherosclerosis, and inflammaging, raising the risk-benefit threshold.

  • Active cancer or recent cancer history: Given LL-37’s dual oncogenic/anti-tumor behavior and lack of long-term human data, exogenous LL-37 is relatively contraindicated during active cancer treatment or within 5 years of diagnosis.

  • Vitamin D status and VDR polymorphisms: Both influence baseline LL-37 production and may shift the therapeutic window; no clear rules for adjusting exogenous dosing exist.

  • Risk-linked HLA and susceptibility polymorphisms: HLA (human leukocyte antigen, immune-identification proteins encoded by a highly variable gene cluster that influences autoimmune-disease risk) variants such as HLA-C*06:02 (the strongest known psoriasis-susceptibility allele) plausibly increase risk of psoriatic flare on exogenous LL-37; HLA alleles tied to lupus and rheumatoid arthritis (e.g., HLA-DRB1 shared epitope variants — a group of class II HLA alleles with a common peptide-binding motif strongly linked to rheumatoid arthritis susceptibility) may similarly elevate autoimmune-flare risk. Direct pharmacogenetic data for LL-37 are not yet available.

Key Interactions & Contraindications

  • Immunosuppressive medications: Drugs such as cyclosporine, methotrexate, TNF-α inhibitors (tumor necrosis factor alpha inhibitors, a biologic class that blocks a central inflammatory cytokine; adalimumab, etanercept, infliximab), JAK inhibitors (Janus kinase inhibitors, small molecules that dampen cytokine signaling; tofacitinib, baricitinib), and corticosteroids act on overlapping inflammatory pathways. Caution; the additive or antagonistic effect of exogenous LL-37 is unpredictable and may blunt immunosuppressive therapy in autoimmune disease.

  • Other immune-modulating peptides: Concurrent use with thymosin-alpha-1, thymosin-beta-4, or BPC-157 is common in peptide-therapy practice; no human data characterize combined pharmacology. Caution.

  • Vitamin D supplementation: Sufficient vitamin D status (25-hydroxyvitamin D 30–50 ng/mL) is an upstream lever for endogenous LL-37; combining high-dose vitamin D with exogenous LL-37 may produce supra-physiological LL-37 activity. Monitor.

  • Sodium butyrate, phenylbutyrate, and short-chain-fatty-acid-producing diets: These induce endogenous LL-37 expression. Additive effect with exogenous LL-37 is possible. Monitor.

  • Topical retinoids, azelaic acid, and ivermectin (rosacea treatments): These reduce LL-37 activity or expression in skin. Topical LL-37 would directly oppose their mechanism. Caution.

  • Supplements with LL-37-potentiating effects: Curcumin, resveratrol, quercetin, and omega-3 fatty acids modulate NLRP3 inflammasome signaling shared with LL-37 activity; direction of interaction is uncertain. Monitor.

  • Anticoagulants and antiplatelet agents (warfarin, apixaban, rivaroxaban, clopidogrel, aspirin): Given LL-37’s pro-coagulant and NET-modulating effects, concurrent use warrants caution. Monitor bleeding or thrombotic signs.

  • Populations who should avoid this intervention:
    • Absolute contraindication: active psoriasis or rosacea, systemic lupus erythematosus, rheumatoid arthritis with active disease, active cancer, pregnancy and lactation (no safety data), children and adolescents.
    • Strong caution: history of cutaneous autoimmune disease in remission, established atherosclerotic cardiovascular disease, chronic coagulation disorders, recent thromboembolic event (<12 months), immunosuppressed transplant recipients.
  • Regulatory status: LL-37 is not FDA-approved for any human indication. It is sold exclusively as “research use only” and is not legal to prescribe or dispense as a drug in the United States; compounding pharmacies may produce it under physician direction, but this sits outside mainstream regulatory pathways.

Risk Mitigation Strategies

  • Screen for autoimmune and inflammatory skin disease before initiation: Take a detailed personal and family history covering psoriasis, rosacea, lupus, rheumatoid arthritis, and inflammatory bowel disease. Examine the skin for subtle rosacea or psoriasiform plaques. Exclude candidates with any active or recent flare to prevent worsening of immune-mediated conditions.

  • Optimize vitamin D status before considering exogenous LL-37: Measure 25-hydroxyvitamin D; target 30–50 ng/mL with oral vitamin D3 supplementation (typical range 2,000–5,000 IU daily, adjusted to levels) before testing any exogenous LL-37, since adequate vitamin D may achieve much of the desired endogenous LL-37 expression without injection risk.

  • Start low, titrate slowly, and stop if flare occurs: Protocols used in peptide-therapy clinics typically begin at 100 µg subcutaneously daily for 5–7 days and increase by 50–100 µg per week as tolerated, with a ceiling of approximately 300–400 µg daily. Discontinue at the first sign of skin flare, new joint pain, or systemic symptoms to avoid triggering autoimmunity.

  • Prefer topical or localized routes where possible: For skin wounds (e.g., diabetic foot ulcers), topical 0.5 mg/mL LL-37 cream applied twice weekly for 4 weeks has trial-grade evidence with no systemic autoimmune signal reported. Prefer local delivery to limit systemic exposure.

  • Verify sourcing through a licensed compounding pharmacy: Use only peptide material from a US FDA-registered 503A or 503B compounding pharmacy with certificates of analysis for identity, purity (>95%), and endotoxin (<10 EU/mg). This mitigates contamination risk and dose-inaccuracy risk inherent to gray-market vials.

  • Cycle rather than use continuously: Standard protocols recommend 4-week on, 2–4-week off cycles, with total duration not exceeding 3 months without reassessment, to reduce the risk of chronic immune stimulation and possible autoantibody formation.

  • Periodic autoimmunity and inflammation monitoring: Check ANA, C-reactive protein, complete blood count with differential, and (in clinically indicated cases) rheumatoid factor and anti-dsDNA (anti–double-stranded DNA antibody, a specific marker of systemic lupus) at baseline and at 3 months to detect emerging autoimmune activity driven by LL-37 exposure.

  • Rotate injection sites and use aseptic technique: Alternate abdomen, thigh, and deltoid sites; use a new sterile needle per dose; disinfect the vial stopper and skin with 70% alcohol to reduce local infection, sterile abscess, and induration.

Therapeutic Protocol

A standard protocol exists informally within peptide-therapy clinics but not in mainstream medicine. The protocol described below reflects how LL-37 is used by integrative and longevity practitioners such as Dr. Craig Koniver and clinicians associated with the International Peptide Society (Dr. William Seeds). The International Peptide Society’s membership derives direct revenue from peptide prescribing and training, which is a relevant financial conflict of interest when weighing its clinical recommendations. No regulatory agency endorses these protocols.

  • Subcutaneous protocol (immune support): 100–200 µg once daily, five days on and two days off, for 4–8 weeks. Typical starting dose is 100 µg per day for the first week, titrated up by 50–100 µg per week to a target of 200–400 µg per day based on tolerance. Injected into subcutaneous fat of abdomen, thigh, or posterior arm using a 0.3 mL insulin syringe.

  • Topical protocol (wound or skin antimicrobial): LL-37 cream at approximately 0.5 mg/mL applied twice weekly for 4 weeks, as used in the diabetic foot ulcer trial (NCT04098562). Best applied to clean, debrided wound beds under occlusive dressing.

  • Intranasal or nebulized protocol (respiratory indications): Not standardized; compounded solutions at 100–500 µg per dose are used in some clinics for chronic sinusitis or post-viral respiratory symptoms. No trial data support efficacy.

  • Intratumoral protocol (melanoma investigational): Dose-escalation protocols evaluated in NCT02225366 used intralesional LL-37; this is confined to clinical research and is not a general-use option.

Competing approaches worth noting without defaulting to one as standard: some practitioners favor LL-37 alone as a first-line immune peptide, while others combine it with thymosin-alpha-1 and BPC-157 as part of a “gut and immune stack.” Dr. William Seeds of the International Peptide Society (whose members derive direct revenue from peptide-based clinical practice) has publicly advocated LL-37 for autoimmune and chronic infection contexts; Dr. Peter Attia’s general peptide framework emphasizes skepticism about peptides without phase III evidence and lists LL-37 as being in the “research-only” category.

  • Best time of day: Most practitioners dose in the morning to align with circadian innate immune activity and to surface any adverse reaction during waking hours.

  • Half-life: LL-37 plasma half-life after subcutaneous dosing is short, on the order of minutes to a few hours due to rapid proteolytic degradation. Local tissue half-life is longer at dosing sites and wound beds.

  • Single vs. split dose: Most protocols use a single daily dose; a small minority uses split AM/PM dosing. There is no comparative human data favoring one over the other.

  • Genetic polymorphisms: VDR polymorphisms (FokI, BsmI, TaqI) may influence the upstream vitamin D axis; CAMP promoter polymorphisms exist but no direct guidance links them to dosing. HLA haplotypes linked to psoriasis, specifically HLA-C*06:02 (the strongest known psoriasis susceptibility allele), may predict heightened risk of psoriatic flare on exogenous LL-37.

  • Sex-based differences: No trial-derived sex-based dose differences exist; women face a higher autoimmune-flare risk and may warrant a lower ceiling.

  • Age-related considerations: Older adults (65+) may warrant lower starting doses (e.g., 50 µg) and slower titration; the reduced injection-site fat in lean older adults changes pharmacokinetics.

  • Baseline biomarkers: Measure 25-hydroxyvitamin D, high-sensitivity C-reactive protein, ANA, complete blood count, and, if skin involvement is a concern, a dermatology exam before dosing.

  • Pre-existing conditions: Diabetes (ulcer healing context), chronic kidney disease (alters peptide clearance), and immunosuppression (transplant, chemotherapy) warrant individualized assessment and lower doses.

Discontinuation & Cycling

  • Lifelong vs. short-term: LL-37 is not intended for lifelong use based on current evidence. Protocols are typically bounded to 4–12 weeks with mandatory breaks.
  • Withdrawal effects: There are no established withdrawal effects for exogenous LL-37.
  • Tapering: No taper schedule is required; practitioners discontinue abruptly at the end of a cycle. If any autoimmune or inflammatory symptom emerges mid-cycle, immediate discontinuation rather than tapering is advised.
  • Cycling: Cycling is recommended by essentially all clinical users, with typical structures of 4 weeks on followed by 2–4 weeks off, or a maximum of 8–12 weeks on with a minimum 4-week washout. The rationale is to limit the potential for chronic immune stimulation, autoantibody formation, and tachyphylaxis (diminished response with repeated dosing).

Sourcing and Quality

  • Source considerations: LL-37 is synthesized by solid-phase peptide synthesis. Research-grade and clinical-grade material differ substantially in purity, endotoxin content, and sterility. Gray-market “research use only” vials are the most common source and have no regulatory guarantee of identity or purity.

  • Third-party testing: Request a Certificate of Analysis specifying peptide identity by mass spectrometry, purity by HPLC (high-performance liquid chromatography, a separation technique for quantifying compound purity) of at least 95–99%, endotoxin <10 EU/mg via LAL (limulus amoebocyte lysate) assay, sterility testing, and residual solvent analysis.

  • Compounding pharmacies: US-based 503A and 503B compounding pharmacies operating under physician prescription are the most reliable option. Examples of pharmacies that have been referenced in peptide-therapy practices include Tailor Made Compounding, Empower Pharmacy, and Strive Pharmacy, though availability and policies change with FDA enforcement actions.

  • Formulation: LL-37 is supplied as a lyophilized powder requiring reconstitution in bacteriostatic water (for multi-use vials) or sterile water (for single-use). Typical reconstitution is 3 mL per 5 mg vial, yielding approximately 1.67 mg/mL; reconstituted material should be refrigerated and used within 2–4 weeks.

  • What to look for: Amber or opaque vials to prevent photodegradation, intact tamper-evident caps, batch and expiry dating, and a paper or digital CoA that accompanies the shipment.

Practical Considerations

  • Time to effect: Topical wound-healing benefits are visible within 1–2 weeks (per NCT04098562 trial). Subjective immune-support outcomes reported anecdotally in peptide-therapy practice appear within 2–4 weeks. No objective clinical time-to-effect data exist for systemic LL-37.

  • Common pitfalls: Initiating LL-37 without screening for subclinical psoriasis, rosacea, or autoimmune disease; using under-dosed gray-market vials with unverified concentration; combining with multiple other peptides simultaneously, making adverse effects difficult to attribute; failing to correct vitamin D deficiency first; continuing dosing through early flare symptoms.

  • Regulatory status: LL-37 is not FDA-approved. It is not on the FDA’s Section 503A bulks list for routine compounding. It is sold exclusively as a research chemical in the United States; use for human administration is legally and ethically gray.

  • Cost and accessibility: Gray-market vials typically run $80–$200 per 5 mg vial, yielding 12–50 doses depending on protocol. Compounded clinical-grade LL-37 through integrative clinics can run $500–$1,500 per cycle including physician oversight. Access is limited to clinics offering peptide therapy, direct-to-consumer peptide vendors (research-use-only), or compounding pharmacies with a prescription.

Interaction with Foundational Habits

  • Sleep: No direct effect on sleep architecture is reported. Indirect effect: LL-37 modulates inflammation, and elevated inflammatory cytokines disrupt sleep; if LL-37 reduces chronic low-grade inflammation in responders, sleep may improve modestly. Morning dosing is preferred to avoid any theoretical activating effect overnight.

  • Nutrition: LL-37 expression is induced by butyrate and short-chain fatty acids produced by fiber fermentation, meaning a high-fiber diet acts synergistically with endogenous LL-37. Alcohol exposure dysregulates LL-37 (per Rojas-Pirela 2026 systematic review): acute use upregulates blood LL-37 while chronic use downregulates hepatic LL-37 and upregulates multiple stress peptides. Vitamin D repletion via food or supplementation is an upstream dietary lever. No specific foods need to be avoided with exogenous dosing.

  • Exercise: No direct interaction with hypertrophy or endurance training is documented. Acute exercise increases neutrophil release of LL-37 transiently; overtraining reduces LL-37 and is associated with upper-respiratory infection risk. Timing exogenous LL-37 around training has no evidence base; morning dosing is typical.

  • Stress management: Chronic psychological stress elevates cortisol and suppresses innate immune function, with downstream reduction in LL-37 activity in some tissues. Stress-reduction practices (sleep, meditation, moderate exercise) support the broader innate immune system in which LL-37 acts. LL-37 has no documented direct interaction with the cortisol axis.

Monitoring Protocol & Defining Success

Baseline testing establishes whether LL-37 is appropriate and provides a reference for detecting adverse trends during dosing. Testing is recommended before any systemic use and at approximately 4–8 weeks of continuous dosing, with longer-interval follow-up (every 3–6 months) during intermittent cycling.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
25-hydroxyvitamin D 40–60 ng/mL Upstream inducer of endogenous LL-37 Conventional lab reference is typically 30–100 ng/mL; functional target is tighter. Fasting not required.
High-sensitivity C-reactive protein (hs-CRP) <1.0 mg/L General inflammation; rises with LL-37-driven immune activation Fasting not required; avoid testing within 2 weeks of acute infection or injury.
Complete blood count (CBC) with differential Neutrophils 2.5–5.0 × 10^9/L; lymphocytes 1.5–3.0 × 10^9/L Detects infection or immune activation Draw at steady time of day; morning preferred.
Antinuclear antibody (ANA) Negative (titer <1:80) Screens for emerging autoimmune response Re-test at 3 months on therapy; positive result warrants specialist referral before continuing.
Anti-LL-37 antibody (if available) Negative Detects LL-37-specific immune response Available only at research labs; not routinely clinically available.
Rheumatoid factor and anti-CCP (anti–cyclic citrullinated peptide antibody) Negative Screens for rheumatoid autoimmunity Test at baseline and 3 months if symptomatic.
Skin examination (dermatology) No active inflammatory lesions Detects subclinical rosacea or psoriasis Repeat if any new facial erythema, papules, or scaling develops.

Ongoing monitoring cadence: repeat hs-CRP and ANA at 4 weeks and at 12 weeks of dosing; repeat CBC at 6 weeks; repeat 25-hydroxyvitamin D every 6–12 months.

Qualitative success markers include:

  • Subjective immune resilience (reduced frequency or severity of respiratory infections over 3–6 months)
  • Wound healing rate (for topical indications)
  • Absence of new skin lesions, facial flushing, or papules
  • Absence of new joint pain, morning stiffness, or Raynaud-like symptoms (color changes of fingers or toes in response to cold or stress, a connective-tissue-disease signal)
  • Stable or improved energy and recovery from exertion
  • No unexplained fatigue, rash, or constitutional symptoms suggesting autoimmune activation

Emerging Research

  • Nano-formulated LL-37 delivery: Research on nanoparticle-conjugated LL-37 aims to extend plasma half-life and target delivery to specific tissues. Reviewed in Wnorowska et al., 2020, discussing magnetic-nanoparticle LL-37 conjugates as next-generation antibiotics. This could strengthen LL-37’s clinical case if local infection indications succeed.

  • LL-37-loaded exosome therapy: Engineered exosomes carrying LL-37 show multi-functional activity (antibacterial, angiogenic, pro-proliferative) in preclinical wound models, per Su et al., 2022. Clinical translation is several years away.

  • Ongoing peri-implant and periodontal trials: NCT06867250 (33 patients, completed 2021, registered 2025) examined peri-implant vitamin D and LL-37 levels in peri-implant disease. NCT07280754 (72 patients, not yet recruiting) is a follow-up evaluating LL-37 and vitamin D biomarkers in peri-implant sulcus fluid.

  • Intralesional LL-37 for melanoma: NCT02225366 completed with a registered enrollment of 4 (3 starting treatment, 2 completing), evaluating intratumoral LL-37 in melanoma. A larger phase I/II program would be needed to validate the anticancer hypothesis.

  • LL-37 cream for diabetic foot ulcer: NCT04098562 (40 patients) produced the primary positive human efficacy signal for topical LL-37, published as Miranda et al., 2023. Replication studies are needed before LL-37 cream becomes a standard diabetic foot ulcer treatment.

  • Cathelicidin-derived short peptides: Yuan et al., 2025 reviews LL-37 derivatives engineered to retain antimicrobial activity while reducing cytotoxicity, pointing toward a next generation of LL-37-inspired therapeutics with potentially better safety profiles.

  • Countervailing evidence streams: Further data clarifying LL-37’s role in atherosclerosis progression, COVID-era thrombosis, and autoimmune flare could tip the risk-benefit balance unfavorably for broad longevity use.

  • Vitamin D axis confirmation: Ongoing trials of vitamin D supplementation in infection contexts continue to test whether endogenous LL-37 upregulation is the mediating mechanism, including completed NCT02464059 (23 patients, COPD (chronic obstructive pulmonary disease, a progressive lung condition)).

Conclusion

Cathelicidin LL-37 is a fascinating molecule that sits at the crossroads of antimicrobial defense, wound healing, and inflammation. It is the only human cathelicidin, and its expression is tied closely to vitamin D status, making vitamin D sufficiency a reasonable first-line way to support endogenous LL-37 activity for anyone interested in innate immunity.

As an exogenous therapy, LL-37 has one well-controlled human trial supporting topical use in diabetic foot ulcers and a small body of investigational work in melanoma, with a clinic-level tradition of subcutaneous use for immune support and chronic infection. Outside of topical wound healing, the human efficacy evidence is thin, and the safety profile is genuinely dual-edged: the same peptide that fights microbes also drives inflammation in psoriasis, rosacea, lupus, and atherosclerosis when expressed in excess or processed abnormally.

The evidence base is also shaped by structural factors. As a naturally occurring human peptide without patent protection, LL-37 has attracted limited large-scale industry investment, and most development sits in the unregulated peptide market or academic early-phase work. Advocacy by peptide-focused groups whose members earn direct revenue from prescribing further tilts the literature.

For an audience focused on innate immunity and longevity, the strongest signal in the current literature sits with vitamin D sufficiency and lifestyle factors that support endogenous LL-37 expression. Exogenous LL-37 currently occupies a narrow evidence base, with most reported use occurring in integrative clinics rather than in controlled clinical settings.

Top - Benefits - Risks - Protocol